NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company dedicated to improving surgical care for patients with neurological disorders, announced its participation in two upcoming medical industry conferences: the American Epilepsy Society (AES) 2025 Annual Meeting and the CNS Drug Delivery Summit.
The AES Annual Meeting will be held in Atlanta, GA from December 5th to December 9th, 2025. According to the company, the conference brings together healthcare providers, scientists, advocates, industry professionals, and others committed to improving outcomes for people with epilepsy. More information about the event can be found on the AES Annual Meeting Registration page.
The CNS Drug Delivery Summit is scheduled for December 9th to 11th, 2025, in Boston, MA. This summit gathers over 100 industry experts, including neuroscientists, chemists, device engineers, and delivery specialists, to discuss cutting-edge strategies for overcoming challenges in accessing the brain. Details are available on the CNS Drug Delivery Conference website.
NeuroOne develops and commercializes minimally invasive, high-definition solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation. These technologies target conditions such as epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain from failed back surgeries, aiming to improve patient outcomes and reduce procedural costs. The company also explores applications for depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence.
The company’s participation in these conferences underscores its commitment to advancing neurological care through innovation and collaboration with the medical community. NeuroOne’s presence at such events provides a platform to showcase its technologies and engage with key stakeholders in the field.
